Everything we've seen

1. ?Nov 12, 3:25 PMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   BAX is down 1.67% with only 20 minutes remaining until the forced close. The move is meaningful but not extreme. The critical limiting factor here is time — with only 20 minutes left, there is very little runway for continuation even if momentum is real. The macro context (T10YIE at 1.7σ below 24-month trend, suppressed inflation expectations) is modestly supportive of defensive/healthcare names like BAX, which could act as a mild headwind against further selling. No news headlines are present to explain or sustain the move, leaving open the possibility this was a technical or flow-driven dip that could stabilize or partially reverse into the close. Late-session dynamics often include profit-taking by short sellers and position squaring, which would create upward pressure and fade the down move. Given the combination of very limited time remaining, no news catalyst to sustain selling, and a macro backdrop not particularly hostile to BAX, the probability of continued downside into the close is below the 0.5 threshold.

2. !Nov 12, 3:25 PMsignalseverity -0.02

   Agent 7 — Day Trader — day_trade_skipped

   BAX is down 1.67% with only 20 minutes remaining until the forced close. The move is meaningful but not extreme. The critical limiting factor here is time — with only 20 minutes left, there is very little runway for continuation even if momentum is real. The macro context (T10YIE at 1.7σ below 24-month trend, suppressed inflation expectations) is modestly supportive of defensive/healthcare names like BAX, which could act as a mild headwind against further selling. No news headlines are present to explain or sustain the move, leaving open the possibility this was a technical or flow-driven dip that could stabilize or partially reverse into the close. Late-session dynamics often include profit-taking by short sellers and position squaring, which would create upward pressure and fade the down move. Given the combination of very limited time remaining, no news catalyst to sustain selling, and a macro backdrop not particularly hostile to BAX, the probability of continued downside into the close is below the 0.5 threshold.

3. ?Nov 12, 10:25 AMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   BAX is down 1.67% today with no attributable headline, suggesting either quiet selling pressure or sector rotation. The move is below the 2-5% threshold that would indicate high-conviction directional flow. Macro context shows 10Y inflation breakevens printing 1.7σ below trend, which is modestly supportive of long-duration/defensive names like BAX (healthcare/medtech), creating a mild headwind against further downside continuation. With 320 minutes remaining there is ample time for the move to extend, but also for a mean-reversion. No news catalyst, moderate move size, and a macro environment that leans slightly defensive together produce a neutral read. Default bias per system rules holds at 0.5 for continuation of the existing downward move.

4. !Nov 12, 10:25 AMsignalseverity -0.02

   Agent 7 — Day Trader — day_trade_skipped

   BAX is down 1.67% today with no attributable headline, suggesting either quiet selling pressure or sector rotation. The move is below the 2-5% threshold that would indicate high-conviction directional flow. Macro context shows 10Y inflation breakevens printing 1.7σ below trend, which is modestly supportive of long-duration/defensive names like BAX (healthcare/medtech), creating a mild headwind against further downside continuation. With 320 minutes remaining there is ample time for the move to extend, but also for a mean-reversion. No news catalyst, moderate move size, and a macro environment that leans slightly defensive together produce a neutral read. Default bias per system rules holds at 0.5 for continuation of the existing downward move.

5. ?Nov 10, 10:10 AMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   BAX is down 2.42% with no headline catalyst, suggesting this is likely flow-driven or sector/macro pressure. The macro context shows DFF elevated 2.0σ above trend, which is modestly negative for capital-intensive healthcare/medtech names like Baxter as higher rates pressure valuations and financing costs. With 335 minutes remaining (essentially a full trading day still ahead), there is ample time for the move to extend. However, the absence of any news makes it harder to assign high conviction — the move could be algorithmic or index-related and prone to fade. No reversal signals are evident from the data provided. The setup is a modest continuation lean: the move is meaningful but not extreme, macro is mildly supportive of downside, and time is sufficient. Probability set just above 0.5 reflecting ordinary momentum with no strong reason to fade.

6. !Nov 10, 10:10 AMsignalseverity -0.02

   Agent 7 — Day Trader — day_trade_skipped

   BAX is down 2.42% with no headline catalyst, suggesting this is likely flow-driven or sector/macro pressure. The macro context shows DFF elevated 2.0σ above trend, which is modestly negative for capital-intensive healthcare/medtech names like Baxter as higher rates pressure valuations and financing costs. With 335 minutes remaining (essentially a full trading day still ahead), there is ample time for the move to extend. However, the absence of any news makes it harder to assign high conviction — the move could be algorithmic or index-related and prone to fade. No reversal signals are evident from the data provided. The setup is a modest continuation lean: the move is meaningful but not extreme, macro is mildly supportive of downside, and time is sufficient. Probability set just above 0.5 reflecting ordinary momentum with no strong reason to fade.

7. ?Nov 9, 3:40 PMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   With only 5 minutes remaining until the forced close cutoff, there is virtually no time for meaningful continuation. The 3.39% move is significant and reflects real conviction, but at this point the trade is essentially over regardless of direction. The risk/reward of entering a position with 5 minutes left is poor — even if momentum continues, there is insufficient time to reach a +3% target from current levels (which would require the stock to move to ~$27.46), and the forced flatten at 3:45 PM ET limits any upside capture. No news catalyst is present to explain the move, and the macro context (elevated mortgage rates) is not particularly relevant to BAX (healthcare/medtech sector). The absence of a clear catalyst combined with the extreme time constraint pushes probability below 0.5. The move may well hold into close, but entering now offers an asymmetric downside given execution risk and the near-zero time window.

8. !Nov 9, 3:40 PMsignalseverity 0.03

   Agent 7 — Day Trader — day_trade_skipped

   With only 5 minutes remaining until the forced close cutoff, there is virtually no time for meaningful continuation. The 3.39% move is significant and reflects real conviction, but at this point the trade is essentially over regardless of direction. The risk/reward of entering a position with 5 minutes left is poor — even if momentum continues, there is insufficient time to reach a +3% target from current levels (which would require the stock to move to ~$27.46), and the forced flatten at 3:45 PM ET limits any upside capture. No news catalyst is present to explain the move, and the macro context (elevated mortgage rates) is not particularly relevant to BAX (healthcare/medtech sector). The absence of a clear catalyst combined with the extreme time constraint pushes probability below 0.5. The move may well hold into close, but entering now offers an asymmetric downside given execution risk and the near-zero time window.

9. ❖Nov 9, 6:23 AMnewsvia finnhub

   Barclays Maintains Underweight on Baxter International, Raises Price Target to $23

   Barclays analyst Christopher Pasquale maintains Baxter International (NYSE:BAX) with a Underweight and raises the price target from $20 to $23.

10. ❖Nov 6, 1:13 PMnewsvia finnhub

    How Return To Profit Will Impact Baxter International Stock (BAX)

    Baxter International reported third quarter 2026 sales of US$2,976 million and net income of US$294 million, and raised its full year sales growth guidance from 4% to 5% from continuing operations. The return to profit over both the quarter and nine month period suggests Baxter International cost actions and portfolio work are starting to show through in reported earnings from continuing operations. This article examines how Baxter International's investment narrative intersects with its...

11. ?Nov 6, 9:45 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is down ~1.89% intraday with 360 minutes remaining (essentially the full session ahead), suggesting this move developed early and there is ample time for either continuation or mean reversion. The move is real but sits just below the 2% threshold that would signal strong conviction flow. No news headlines are available to explain the driver, which is neutral per guidance but leaves the catalyst unclear — could be sector rotation, light selling pressure, or a small negative catalyst not yet captured. The macro context (elevated mortgage rates at 1.9σ above trend) is not directly relevant to BAX, a healthcare/med-tech company (Baxter International), offering neither tailwind nor headwind from that specific print. With 360 minutes remaining there is plenty of time for continuation, but with no clear catalyst, no sector tailwind for the downside, and a move that has not yet broken into the 2-5% 'conviction' range, this is a borderline read. I lean marginally toward continuation given the system's asymmetric risk/reward and the guidance to resolve borderline reads toward the trade, but conviction is low — probability set at the floor threshold.

12. !Nov 6, 9:45 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    BAX is down ~1.89% intraday with 360 minutes remaining (essentially the full session ahead), suggesting this move developed early and there is ample time for either continuation or mean reversion. The move is real but sits just below the 2% threshold that would signal strong conviction flow. No news headlines are available to explain the driver, which is neutral per guidance but leaves the catalyst unclear — could be sector rotation, light selling pressure, or a small negative catalyst not yet captured. The macro context (elevated mortgage rates at 1.9σ above trend) is not directly relevant to BAX, a healthcare/med-tech company (Baxter International), offering neither tailwind nor headwind from that specific print. With 360 minutes remaining there is plenty of time for continuation, but with no clear catalyst, no sector tailwind for the downside, and a move that has not yet broken into the 2-5% 'conviction' range, this is a borderline read. I lean marginally toward continuation given the system's asymmetric risk/reward and the guidance to resolve borderline reads toward the trade, but conviction is low — probability set at the floor threshold.

13. ?Nov 5, 2:31 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is down 4.72% with no attributable headline, suggesting institutional selling pressure or a sector/name-specific catalyst not yet surfaced in news feeds. The move is meaningful in magnitude and represents real flow. Macro context shows elevated fed funds rate (3.88, 2.1σ above trend), which is a mild headwind for capital-intensive medtech/healthcare names like Baxter but not a direct sector driver here. With 75 minutes remaining there is sufficient time for continuation toward the close, though not ample runway for a large additional leg. No reversal signals are evident from the data provided — no fade pattern described, no news-driven spike-and-reverse dynamic. Absent a clear reason to expect a mean reversion, the default lean is mild continuation per the system's bias toward action on borderline reads. Probability is kept modest at 0.52 given: (1) no confirming catalyst, (2) the move may already be largely complete at this magnitude, and (3) elevated rates macro context is not specifically bearish for BAX's business model today.

14. !Nov 5, 2:31 PMsignalseverity -0.05

    Agent 7 — Day Trader — day_trade_skipped

    BAX is down 4.72% with no attributable headline, suggesting institutional selling pressure or a sector/name-specific catalyst not yet surfaced in news feeds. The move is meaningful in magnitude and represents real flow. Macro context shows elevated fed funds rate (3.88, 2.1σ above trend), which is a mild headwind for capital-intensive medtech/healthcare names like Baxter but not a direct sector driver here. With 75 minutes remaining there is sufficient time for continuation toward the close, though not ample runway for a large additional leg. No reversal signals are evident from the data provided — no fade pattern described, no news-driven spike-and-reverse dynamic. Absent a clear reason to expect a mean reversion, the default lean is mild continuation per the system's bias toward action on borderline reads. Probability is kept modest at 0.52 given: (1) no confirming catalyst, (2) the move may already be largely complete at this magnitude, and (3) elevated rates macro context is not specifically bearish for BAX's business model today.

15. ?Nov 5, 11:55 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is down 3.70% intraday with no attributable headline, suggesting this is likely flow-driven or sector/market-wide pressure rather than a specific catalyst. The move is meaningful in magnitude and represents real conviction from sellers. With 230 minutes remaining (nearly a full session still ahead), there is ample time for continuation. However, several factors temper confidence: (1) No news catalyst means the move could fade as the initial selling pressure exhausts itself; (2) The macro context (elevated DFF at 2.1σ above trend) is more directly relevant to banks and money-market funds, not healthcare/medtech names like BAX, so there is no macro tailwind for continued selling specific to this sector; (3) At ~3.70% down, BAX is approaching a level where short-term mean-reversion buyers may step in, especially in the absence of a fundamental story. The setup doesn't show clear continuation pressure (no news, no sector-specific macro driver), but the momentum itself is real and 230 minutes is enough time for a further leg. Assigning a modest continuation probability just above the threshold — the bounded risk profile justifies taking the trade, but this is a low-conviction read.

16. !Nov 5, 11:55 AMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    BAX is down 3.70% intraday with no attributable headline, suggesting this is likely flow-driven or sector/market-wide pressure rather than a specific catalyst. The move is meaningful in magnitude and represents real conviction from sellers. With 230 minutes remaining (nearly a full session still ahead), there is ample time for continuation. However, several factors temper confidence: (1) No news catalyst means the move could fade as the initial selling pressure exhausts itself; (2) The macro context (elevated DFF at 2.1σ above trend) is more directly relevant to banks and money-market funds, not healthcare/medtech names like BAX, so there is no macro tailwind for continued selling specific to this sector; (3) At ~3.70% down, BAX is approaching a level where short-term mean-reversion buyers may step in, especially in the absence of a fundamental story. The setup doesn't show clear continuation pressure (no news, no sector-specific macro driver), but the momentum itself is real and 230 minutes is enough time for a further leg. Assigning a modest continuation probability just above the threshold — the bounded risk profile justifies taking the trade, but this is a low-conviction read.

17. ✓Nov 4, 9:30 AMdecisionacted

    Agent 8 — Dip Buyer (Peer-Aware) — pyramid

    Pyramid add-on fired at +12.11% unrealized. Added 25 sh @ $26.33 ($658.25). Position now 76 sh @ weighted avg $24.42.

18. ❖Nov 4, 5:29 AMnewsvia finnhub

    Baxter International Stock: Analyst Estimates & Ratings

    Baxter International has outperformed the broader market despite declining earnings, while higher guidance and debt reduction support optimism amid neutral analyst sentiment.

19. ▣Nov 3, 7:00 PMjournaltarget

    Agent 8 — Dip Buyer (Peer-Aware) closed long 38 @ $26.27 (+$70.27)

    Staged exit (1/2.0): close $26.27 ≥ target $26.10. Selling 38/76 sh, trailing remainder.

20. ❖Nov 3, 2:54 PMnewsvia finnhub

    Should You Buy Baxter Stock For Its Cash?

    For questions about this article or underlying research, email help@trefis.com.

21. ?Nov 3, 1:25 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is up 3.14% intraday with no headline catalyst identified, suggesting the move is flow-driven rather than news-driven. The macro context (elevated DFF at 2.2σ above trend) is primarily relevant to banks and money-market funds, not healthcare/medtech names like Baxter International, so macro tailwinds/headwinds are largely neutral here. With 140 minutes remaining there is reasonable time for continuation, but the absence of a clear catalyst means the move could be fully priced in or subject to profit-taking as the session matures. No reversal signal is evident, and the magnitude (just over 3%) is meaningful but not extreme. On balance, slight lean toward continuation given momentum and adequate time, but conviction is modest.

22. !Nov 3, 1:25 PMsignalseverity 0.03

    Agent 7 — Day Trader — day_trade_skipped

    BAX is up 3.14% intraday with no headline catalyst identified, suggesting the move is flow-driven rather than news-driven. The macro context (elevated DFF at 2.2σ above trend) is primarily relevant to banks and money-market funds, not healthcare/medtech names like Baxter International, so macro tailwinds/headwinds are largely neutral here. With 140 minutes remaining there is reasonable time for continuation, but the absence of a clear catalyst means the move could be fully priced in or subject to profit-taking as the session matures. No reversal signal is evident, and the magnitude (just over 3%) is meaningful but not extreme. On balance, slight lean toward continuation given momentum and adequate time, but conviction is modest.

23. ?Nov 2, 10:01 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is up ~3.96% intraday with no attributable headline, suggesting this is flow-driven — likely institutional positioning or sector rotation. The move is meaningful and represents real conviction. However, several factors temper enthusiasm: (1) 345 minutes remaining is actually a full trading day (market opens at ~9:30 AM ET and closes at 3:45 PM cutoff, so 345 minutes suggests this is very early in the session, giving ample time but also risk of mean reversion), (2) no news catalyst makes the move harder to sustain as momentum traders may take profits, (3) the macro backdrop (elevated mortgage rates at 7.24%, 2.3σ above trend) is broadly negative for financials and rate-sensitive sectors — BAX is a healthcare/medtech company so macro is largely neutral here, not a tailwind. The absence of a clear catalyst and the lack of sector tailwind keep this from being a high-conviction continuation. With tight stops and a fixed profit target, the asymmetric payoff structure supports taking the trade at a modest probability above 0.5, reflecting ordinary momentum without strong fade signals.

24. !Nov 2, 10:01 AMsignalseverity 0.04

    Agent 7 — Day Trader — day_trade_skipped

    BAX is up ~3.96% intraday with no attributable headline, suggesting this is flow-driven — likely institutional positioning or sector rotation. The move is meaningful and represents real conviction. However, several factors temper enthusiasm: (1) 345 minutes remaining is actually a full trading day (market opens at ~9:30 AM ET and closes at 3:45 PM cutoff, so 345 minutes suggests this is very early in the session, giving ample time but also risk of mean reversion), (2) no news catalyst makes the move harder to sustain as momentum traders may take profits, (3) the macro backdrop (elevated mortgage rates at 7.24%, 2.3σ above trend) is broadly negative for financials and rate-sensitive sectors — BAX is a healthcare/medtech company so macro is largely neutral here, not a tailwind. The absence of a clear catalyst and the lack of sector tailwind keep this from being a high-conviction continuation. With tight stops and a fixed profit target, the asymmetric payoff structure supports taking the trade at a modest probability above 0.5, reflecting ordinary momentum without strong fade signals.

25. ?Nov 2, 9:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BAX is down 10% from its 30-day high with no visible fundamental deterioration from the sparse 8-K filings (no metrics flagging guidance cuts, covenant breaches, or going-concern language). The Health Care sector (XLV) ranks 1st of 11 sectors by 30-day relative strength with strong outperformance vs. SPY (+4.70pts over 30 days), meaning this appears to be a single-stock idiosyncratic dip within an outperforming sector. Options flow on 2026-10-28 shows unusually elevated call volume (z=4.00) alongside a put/call ratio of 0.59, suggesting informed buyers are positioning for a recovery despite the broader market weakness today.

26. ?Oct 30, 4:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BAX is down 10% from its 30-day high with no visible fundamental deterioration from the sparse 8-K filings (no metrics flagging guidance cuts, covenant breaches, or going-concern language). The Health Care sector (XLV) ranks 1st of 11 sectors by 30-day relative strength with strong outperformance vs. SPY (+4.70pts over 30 days), meaning this appears to be a single-stock idiosyncratic dip within an outperforming sector. Options flow on 2026-10-28 shows unusually elevated call volume (z=4.00) alongside a put/call ratio of 0.59, suggesting informed buyers are positioning for a recovery despite the broader market weakness today.

27. ❖Oct 30, 3:38 PMnewsvia finnhub

    JP Morgan Maintains Neutral on Baxter International, Lowers Price Target to $25

    JP Morgan analyst Robbie Marcus maintains Baxter International (NYSE:BAX) with a Neutral and lowers the price target from $26 to $25.

28. ?Oct 30, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BAX is down 10% from its 30-day high with no visible fundamental deterioration from the sparse 8-K filings (no metrics flagging guidance cuts, covenant breaches, or going-concern language). The Health Care sector (XLV) ranks 1st of 11 sectors by 30-day relative strength with strong outperformance vs. SPY (+4.70pts over 30 days), meaning this appears to be a single-stock idiosyncratic dip within an outperforming sector. Options flow on 2026-10-28 shows unusually elevated call volume (z=4.00) alongside a put/call ratio of 0.59, suggesting informed buyers are positioning for a recovery despite the broader market weakness today.

29. ?Oct 30, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BAX is down 10% from its 30-day high with no visible fundamental deterioration from the sparse 8-K filings (no metrics flagging guidance cuts, covenant breaches, or going-concern language). The Health Care sector (XLV) ranks 1st of 11 sectors by 30-day relative strength with strong outperformance vs. SPY (+4.70pts over 30 days), meaning this appears to be a single-stock idiosyncratic dip within an outperforming sector. Options flow on 2026-10-28 shows unusually elevated call volume (z=4.00) alongside a put/call ratio of 0.59, suggesting informed buyers are positioning for a recovery despite the broader market weakness today.

30. ❖Oct 30, 12:02 PMnewsvia finnhub

    BAX Q3 deep dive: cost actions and product changes shape outlook amid market caution

    Healthcare company Baxter International (NYSE:BAX) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 5% year on year to $2.98 billion. Its non-GAAP profit of $0.58 per share was 11.9% above analysts’ consensus estimates.

31. ?Oct 30, 11:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BAX is down 10% from its 30-day high with no visible fundamental deterioration from the sparse 8-K filings (no metrics flagging guidance cuts, covenant breaches, or going-concern language). The Health Care sector (XLV) ranks 1st of 11 sectors by 30-day relative strength with strong outperformance vs. SPY (+4.70pts over 30 days), meaning this appears to be a single-stock idiosyncratic dip within an outperforming sector. Options flow on 2026-10-28 shows unusually elevated call volume (z=4.00) alongside a put/call ratio of 0.59, suggesting informed buyers are positioning for a recovery despite the broader market weakness today.

32. ?Oct 30, 10:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] BAX is down 10% from its 30-day high with no visible fundamental deterioration from the sparse 8-K filings (no metrics flagging guidance cuts, covenant breaches, or going-concern language). The Health Care sector (XLV) ranks 1st of 11 sectors by 30-day relative strength with strong outperformance vs. SPY (+4.70pts over 30 days), meaning this appears to be a single-stock idiosyncratic dip within an outperforming sector. Options flow on 2026-10-28 shows unusually elevated call volume (z=4.00) alongside a put/call ratio of 0.59, suggesting informed buyers are positioning for a recovery despite the broader market weakness today.

33. ❖Oct 30, 8:48 AMnewsvia finnhub

    Wells Fargo Maintains Equal-Weight on Baxter International, Raises Price Target to $25

    Wells Fargo analyst Larry Biegelsen maintains Baxter International (NYSE:BAX) with a Equal-Weight and raises the price target from $23 to $25.

34. ❖Oct 30, 8:30 AMnewsvia finnhub

    Baxter International Inc. Q3 2026 Earnings Call Summary

    Moby summary of Baxter International Inc.'s Q3 2026 earnings call

35. ❖Oct 30, 7:59 AMnewsvia finnhub

    Baxter’s shares fall as Q3 probability dips despite revenue growth

    Baxter’s shares fell by over 4% on 29 October after adjusted earnings per share (EPS) dipped 16% year-over-year, despite positive revenue results.

36. ❖Oct 30, 3:14 AMnewsvia finnhub

    What Baxter International (BAX) Said on Its Q3 Earnings Call

    Baxter International (NYSE:BAX) raised its full-year 2026 outlook after reporting third-quarter sales and adjusted earnings that exceeded its expectations, citing broad-based growth across its portfolio, improving execution and strong free cash flow generation. Third-quarter global sales totaled ab

37. ❖Oct 29, 9:19 PMnewsvia finnhub

    Baxter International Inc. 2026 Q3 - Results - Earnings Call Presentation

    2026-10-30. The following slide deck was published by Baxter International Inc.

38. ❖Oct 29, 9:17 PMnewsvia finnhub

    Baxter International (BAX) Received An FDA Warning Letter Over CGMP Violations

    Baxter International (NYSE:BAX) received an FDA warning letter citing multiple CGMP violations at a U.S. drug manufacturing site. The FDA cited cross contamination risks and weaknesses in aseptic processing controls that affect certain sterile pharmaceutical products. The letter outlines required corrective actions and also signals possible further FDA enforcement if Baxter does not remediate the issues. The FDA warning letter on CGMP and contamination problems at Baxter's facility sits in...

39. ?Oct 29, 4:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: buy

    [not executed — reserve_floor_or_cash] BAX is down 10% from its 30-day high with no visible fundamental deterioration from the sparse 8-K filings (no metrics flagging guidance cuts, covenant breaches, or going-concern language). The Health Care sector (XLV) ranks 1st of 11 sectors by 30-day relative strength with strong outperformance vs. SPY (+4.70pts over 30 days), meaning this appears to be a single-stock idiosyncratic dip within an outperforming sector. Options flow on 2026-10-28 shows unusually elevated call volume (z=4.00) alongside a put/call ratio of 0.59, suggesting informed buyers are positioning for a recovery despite the broader market weakness today.

40. ✓Oct 29, 4:21 PMdecisionacted

    Agent 8 — Dip Buyer (Peer-Aware) — decide: buy

    BAX is down 10% from its 30-day high with no confirmed fundamental negative catalyst — no negative headlines, no earnings miss, and no insider selling. The options flow shows unusual call volume (z=4.00) with a low P/C ratio of 0.59, suggesting informed bullish positioning on the dip. Healthcare (XLV) is the top-ranked sector by 30-day relative strength with strong positive flow, which is supportive — the dip appears idiosyncratic rather than sector-driven, meaning a mean-reversion back toward prior highs is plausible.

41. ❖Oct 29, 4:06 PMnewsvia finnhub

    S&P 500 Top Movers: Oct. 29, 2026 Gainers and Losers

    S&P 500 top movers for Oct. 29, 2026, led by CVNA and GEN among gainers and NOW and FTNT among losers.

42. ❖Oct 29, 2:29 PMnewsvia finnhub

    Baxter (BAX) Q3 2026 Earnings Call Transcript

    Revenue hit $3 billion with 5% organic growth; guidance raised on momentum.

43. ❖Oct 29, 2:10 PMnewsvia finnhub

    Baxter International Inc. Reports Third-Quarter 2026 Results and Declares Quarterly Cash Dividend of $0.01 Per Share

44. ❖Oct 29, 1:36 PMnewsvia finnhub

    S&P 500 Top Movers: Today's US Session Gainers and Losers

    S&P 500 top movers for today's US session: Carvana and Textron lead gainers, while ServiceNow and Fortinet post the steepest declines.

45. ?Oct 29, 12:55 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is down 6.15% intraday with no attributable headline, suggesting this is either a large institutional seller working an order or a delayed reaction to some fundamental development (earnings revision, guidance cut, sector rotation). A move of this magnitude typically reflects real conviction and size. With 170 minutes remaining there is meaningful time for continuation pressure to persist into the close. However, several factors temper enthusiasm: (1) no news catalyst means we cannot confirm the thesis or estimate how much selling remains; (2) at -6.15% from the prior close, BAX is already deep intraday and mean-reversion pressure builds as the session matures; (3) the macro backdrop (T10Y2Y at 0.29, 1.7σ below trend, bear-flattening environment) is modestly supportive of defensive sectors like healthcare/med-devices where BAX competes, which could attract dip buyers; (4) no confirming sector-wide breakdown is noted. On balance, the raw momentum and time remaining edge the probability slightly above 0.5 toward continuation, but the absence of a catalyst and defensive-sector macro support prevent a high-conviction call. Probability set at 0.54 — marginal continuation trade with tight stop discipline essential.

46. !Oct 29, 12:55 PMsignalseverity -0.06

    Agent 7 — Day Trader — day_trade_skipped

    BAX is down 6.15% intraday with no attributable headline, suggesting this is either a large institutional seller working an order or a delayed reaction to some fundamental development (earnings revision, guidance cut, sector rotation). A move of this magnitude typically reflects real conviction and size. With 170 minutes remaining there is meaningful time for continuation pressure to persist into the close. However, several factors temper enthusiasm: (1) no news catalyst means we cannot confirm the thesis or estimate how much selling remains; (2) at -6.15% from the prior close, BAX is already deep intraday and mean-reversion pressure builds as the session matures; (3) the macro backdrop (T10Y2Y at 0.29, 1.7σ below trend, bear-flattening environment) is modestly supportive of defensive sectors like healthcare/med-devices where BAX competes, which could attract dip buyers; (4) no confirming sector-wide breakdown is noted. On balance, the raw momentum and time remaining edge the probability slightly above 0.5 toward continuation, but the absence of a catalyst and defensive-sector macro support prevent a high-conviction call. Probability set at 0.54 — marginal continuation trade with tight stop discipline essential.

47. ❖Oct 29, 10:48 AMnewsvia finnhub

    Baxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook Raised

    BAX beats Q3 earnings and revenue estimates, driven by broad-based segment growth, and raises its 2026 outlook despite continued margin pressure.

48. ?Oct 29, 9:55 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is down 5.85% intraday with no attributable headline, suggesting this is driven by institutional selling or sector rotation rather than a single catalyst. A move of this magnitude represents real conviction and size. With 350 minutes remaining (approximately 5.8 hours — notably, that appears to be a very long time, possibly indicating early session), there is ample time for the move to continue or develop further. The macro context shows T10Y2Y at 1.7σ below trend, which is modestly supportive of defensives in a bear-flattening regime, but BAX as a medtech/healthcare name is not a pure rate-sensitive defensive play and the spread signal is not extreme enough to be a clear tailwind here. No reversal signal is evident — no mention of a fade off lows or recovering price action. The absence of news does not disqualify continuation; large uninformed moves often persist intraday as momentum traders pile in and initial sellers are not exhausted. Given the lack of a clear reversal catalyst, meaningful time remaining, and a sizable initial move suggesting real flow, the base case is modest continuation downward. Probability stays conservative at 0.54 given no volume data to confirm conviction and the lack of any sector headline to anchor the move.

49. !Oct 29, 9:55 AMsignalseverity -0.06

    Agent 7 — Day Trader — day_trade_skipped

    BAX is down 5.85% intraday with no attributable headline, suggesting this is driven by institutional selling or sector rotation rather than a single catalyst. A move of this magnitude represents real conviction and size. With 350 minutes remaining (approximately 5.8 hours — notably, that appears to be a very long time, possibly indicating early session), there is ample time for the move to continue or develop further. The macro context shows T10Y2Y at 1.7σ below trend, which is modestly supportive of defensives in a bear-flattening regime, but BAX as a medtech/healthcare name is not a pure rate-sensitive defensive play and the spread signal is not extreme enough to be a clear tailwind here. No reversal signal is evident — no mention of a fade off lows or recovering price action. The absence of news does not disqualify continuation; large uninformed moves often persist intraday as momentum traders pile in and initial sellers are not exhausted. Given the lack of a clear reversal catalyst, meaningful time remaining, and a sizable initial move suggesting real flow, the base case is modest continuation downward. Probability stays conservative at 0.54 given no volume data to confirm conviction and the lack of any sector headline to anchor the move.

50. ❖Oct 29, 9:21 AMnewsvia finnhub

    What Sent GE HealthCare Stock Higher?

    For questions about this article or underlying research, email help@trefis.com.

51. ❖Oct 29, 8:46 AMnewsvia finnhub

    Baxter (NYSE:BAX) surprises with Q3 2026 sales

    Healthcare company Baxter International (NYSE:BAX) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 5% year on year to $2.98 billion. Its non-GAAP profit of $0.58 per share was 11.9% above analysts’ consensus estimates.

52. ❖Oct 29, 8:30 AMnewsvia finnhub

    Compared to Estimates, Baxter (BAX) Q3 Earnings: A Look at Key Metrics

    The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

53. ❖Oct 29, 8:28 AMnewsvia finnhub

    Baxter International Inc. (BAX) Q3 2026 Earnings Call Transcript

    Baxter International Inc. (BAX) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDTCompany ParticipantsKevin Moran - Vice President & Head of Investor...

54. ❖Oct 29, 8:08 AMnewsvia finnhub

    Why Is Baxter Stock Trading Lower on Thursday?

    Baxter tops Q3 consensus with 58 cents EPS and $2.976 billion in sales, lifting fiscal 2026 profit and revenue guidance above Wall Street forecasts.

55. ❖Oct 29, 7:35 AMnewsvia finnhub

    Baxter International (BAX) Q3 Earnings and Revenues Surpass Estimates

    Baxter (BAX) delivered earnings and revenue surprises of +13.73% and +2.48%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

56. ❖Oct 29, 7:26 AMnewsvia finnhub

    Baxter: Q3 Earnings Snapshot

    (AP) — Baxter International Inc. (BAX) on Thursday reported third-quarter net income of $294 million, after reporting a loss in the same period a year earlier.

57. ❖Oct 29, 6:10 AMnewsvia finnhub

    Baxter International Inc (NYSE:BAX) Breakout Setup Shows Technical Strength

    A technical breakout screen combining ChartMill Technical Rating and Setup Quality flags Baxter (BAX) as a healthy trend with a defined entry.

58. ❖Oct 29, 5:42 AMnewsvia finnhub

    Baxter Intl Q3 2026 Earnings Call Transcript

    Baxter Intl (NYSE:BAX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For

59. ❖Oct 29, 3:17 AMnewsvia finnhub

    Baxter International Raises FY2026 Adj EPS Guidance from $1.95-$2.15 to $2.05-$2.15 vs $2.05 Est; Raises FY2026 Sales Guidance from $11.581B-$11.694B to $11.694B-$11.806B vs $11.619B Est

    Baxter International (NYSE:BAX) raises FY2026 Adj EPS guidance from $1.95-$2.15 to $2.05-$2.15 vs $2.05 analyst estimate. Raises FY2026 sales outlook from $11.581 billion-$11.694 billion to $11.694 billion-$11.806

60. ▢Oct 28, 8:00 PMjournal

    Agent 8 — Dip Buyer (Peer-Aware) opened long 38 @ $24.42

61. ?Oct 28, 10:25 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is up 3.17% intraday with no attributable headline, suggesting real institutional flow drove the move. The move is meaningful in magnitude and represents genuine conviction from someone with size. However, several factors temper enthusiasm: (1) With 320 minutes remaining (over 5 hours), there is ample time for reversion, but also for continuation — time is neutral to slightly favorable. (2) The macro context shows T10Y2Y at 1.7σ below trend, a flattening/mildly inverted curve environment that favors defensives — BAX as a healthcare/medical supplies company is a defensive name, which is marginally supportive of the bid. (3) No news catalyst means we cannot confirm whether this is a sustained strategic accumulation or a one-off block trade that has already exhausted itself. (4) Without volume data confirming the move, we cannot rule out thin-volume drift. Given BAX's defensive character aligning with the macro backdrop (bear-flattening favors defensives), and the real-flow signal embedded in a 3%+ move, a modest continuation probability above the 0.5 threshold is warranted, but not strongly so. No clear fade signal present.

62. !Oct 28, 10:25 AMsignalseverity 0.03

    Agent 7 — Day Trader — day_trade_skipped

    BAX is up 3.17% intraday with no attributable headline, suggesting real institutional flow drove the move. The move is meaningful in magnitude and represents genuine conviction from someone with size. However, several factors temper enthusiasm: (1) With 320 minutes remaining (over 5 hours), there is ample time for reversion, but also for continuation — time is neutral to slightly favorable. (2) The macro context shows T10Y2Y at 1.7σ below trend, a flattening/mildly inverted curve environment that favors defensives — BAX as a healthcare/medical supplies company is a defensive name, which is marginally supportive of the bid. (3) No news catalyst means we cannot confirm whether this is a sustained strategic accumulation or a one-off block trade that has already exhausted itself. (4) Without volume data confirming the move, we cannot rule out thin-volume drift. Given BAX's defensive character aligning with the macro backdrop (bear-flattening favors defensives), and the real-flow signal embedded in a 3%+ move, a modest continuation probability above the 0.5 threshold is warranted, but not strongly so. No clear fade signal present.

63. ❖Oct 28, 3:10 AMnewsvia finnhub

    Baxter (BAX) Q3 earnings: what to expect

    Healthcare company Baxter International (NYSE:BAX) will be announcing earnings results this Thursday before market hours. Here’s what you need to know.

64. ?Oct 20, 6:21 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — skip

    [distribution] The 20-day PV path tells a clear distributional story. After a quiet accumulation attempt in early October (the Oct 5 surge to $24.22 on 10.2M and the Oct 12–15 grind to a peak of $25.76 on declining volume of 4.5M), the path has pivoted decisively down-and-right: the last three sessions (Oct 16 –1.86% on 4.4M, Oct 19 –1.15% on 5.3M, Oct 20 –1.92% on 12.2M) show net negative price movement on sharply expanding volume — today's 12.2M print is nearly 2× the prior session and carries a z-score of 3.15 versus the 20-day ADV of 6.2M. Critically, this heavy-volume down bar arrives after price had already failed to hold the Oct 15 high of $25.76, with subsequent sessions unable to reclaim even $25.00, confirming sellers are using volume spikes to exit rather than buyers using them to enter. The three-session sub-path satisfies two of the three bearish-confirmation criteria required even under a bull-regime override: (1) price recently hit a multi-week high ($25.76) and today's volume is ~1.97× the 20-day ADV, and (2) the most recent 3-session sub-path shows net negative price movement (–$1.25 from $25.76 to $24.51) on expanding volume — warranting the distribution label rather than no_pattern. Risks: A reversal above $25.76 on volume exceeding today's 12.2M would invalidate the distributional read and reopen the bullish case; the macro backdrop of elevated 2-year yields (4.74, +2.0σ) adds sector-agnostic headwind but is not specific to Health Care, so any broad risk-on pivot or sector rotation into defensives could rapidly shift the PV path back into accumulation territory.

65. ?Oct 20, 10:01 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is down 4.08% today with no attributable headline, suggesting this is either a technical breakdown or quiet institutional selling. The move is meaningful in magnitude and represents real flow. However, several factors temper conviction: (1) No news catalyst means the move could be exhaustion-driven or a single large seller who may be done, (2) The macro context of elevated 2-year yields (4.74, 2σ above trend) is not particularly negative for BAX — it is a healthcare/medtech name, not a bank or long-duration tech play, so rate pressure is not a direct accelerant here, (3) 345 minutes remaining is actually substantial time for continuation, which is a mild positive for the directional thesis, (4) Without volume data it is hard to confirm institutional conviction behind the move. Balancing a real 4%+ move (genuine evidence of selling pressure) against the absence of a catalyst, neutral macro relevance for this sector, and no confirmation of volume, this is a borderline continuation setup. Probability set just above 0.5 to reflect modest momentum bias without strong amplifying factors.

66. !Oct 20, 10:01 AMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    BAX is down 4.08% today with no attributable headline, suggesting this is either a technical breakdown or quiet institutional selling. The move is meaningful in magnitude and represents real flow. However, several factors temper conviction: (1) No news catalyst means the move could be exhaustion-driven or a single large seller who may be done, (2) The macro context of elevated 2-year yields (4.74, 2σ above trend) is not particularly negative for BAX — it is a healthcare/medtech name, not a bank or long-duration tech play, so rate pressure is not a direct accelerant here, (3) 345 minutes remaining is actually substantial time for continuation, which is a mild positive for the directional thesis, (4) Without volume data it is hard to confirm institutional conviction behind the move. Balancing a real 4%+ move (genuine evidence of selling pressure) against the absence of a catalyst, neutral macro relevance for this sector, and no confirmation of volume, this is a borderline continuation setup. Probability set just above 0.5 to reflect modest momentum bias without strong amplifying factors.

67. ?Oct 16, 2:30 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is down 2.43% intraday with no identifiable news catalyst. The move is meaningful in magnitude and likely reflects real institutional flow, but the absence of a headline means we cannot assess whether the catalyst is exhausted or ongoing. The macro context (elevated mortgage rates at 3.3σ above trend) is not directly relevant to BAX, a healthcare/medical products company, so it provides neither tailwind nor headwind for continuation. With 75 minutes remaining until the forced close, there is adequate time for the move to extend, but also enough time for a partial mean-reversion if early sellers have been satisfied. No reversal signals are explicitly present, and no volume abnormality is noted. Given the bounded risk profile of the system (1.5% stop, 3% target, forced flatten at 3:45), the default lean on a >2% move with no contraindication resolves marginally in favor of continuation. Assigning 0.5 — the minimum threshold — as there is no strong confirming evidence beyond price action alone.

68. !Oct 16, 2:30 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    BAX is down 2.43% intraday with no identifiable news catalyst. The move is meaningful in magnitude and likely reflects real institutional flow, but the absence of a headline means we cannot assess whether the catalyst is exhausted or ongoing. The macro context (elevated mortgage rates at 3.3σ above trend) is not directly relevant to BAX, a healthcare/medical products company, so it provides neither tailwind nor headwind for continuation. With 75 minutes remaining until the forced close, there is adequate time for the move to extend, but also enough time for a partial mean-reversion if early sellers have been satisfied. No reversal signals are explicitly present, and no volume abnormality is noted. Given the bounded risk profile of the system (1.5% stop, 3% target, forced flatten at 3:45), the default lean on a >2% move with no contraindication resolves marginally in favor of continuation. Assigning 0.5 — the minimum threshold — as there is no strong confirming evidence beyond price action alone.

69. ?Oct 9, 3:35 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    BAX is up 2.07% with only 10 minutes remaining until the forced close at 3:45 PM ET. The move is meaningful in magnitude, suggesting real institutional flow, but the critical constraint here is time — with just 10 minutes left, there is virtually no runway for continuation to reach the +3% profit target from current levels (would need roughly another ~0.9% from here). The macro context (elevated mortgage rates at 3.8σ above trend) is not directly relevant to BAX (medical devices/healthcare), providing no tailwind or headwind. No news catalysts are present. At this stage of the session, end-of-day positioning, profit-taking, and mean reversion forces tend to dominate over momentum continuation. The risk/reward of entering a momentum trade with 10 minutes left and needing ~1% more upside is unfavorable even with bounded downside. Probability set below 0.5 primarily due to extreme time constraint, not because the underlying move lacks conviction.

70. !Oct 9, 3:35 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    BAX is up 2.07% with only 10 minutes remaining until the forced close at 3:45 PM ET. The move is meaningful in magnitude, suggesting real institutional flow, but the critical constraint here is time — with just 10 minutes left, there is virtually no runway for continuation to reach the +3% profit target from current levels (would need roughly another ~0.9% from here). The macro context (elevated mortgage rates at 3.8σ above trend) is not directly relevant to BAX (medical devices/healthcare), providing no tailwind or headwind. No news catalysts are present. At this stage of the session, end-of-day positioning, profit-taking, and mean reversion forces tend to dominate over momentum continuation. The risk/reward of entering a momentum trade with 10 minutes left and needing ~1% more upside is unfavorable even with bounded downside. Probability set below 0.5 primarily due to extreme time constraint, not because the underlying move lacks conviction.

71. ?Oct 9, 7:00 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

72. !Oct 9, 7:00 AMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

73. ?Oct 9, 7:00 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

74. !Oct 9, 7:00 AMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

75. ?Oct 8, 2:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

76. !Oct 8, 2:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

77. ?Oct 8, 2:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

78. !Oct 8, 2:20 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

79. ?Oct 8, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

80. !Oct 8, 1:20 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

81. ?Oct 8, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

82. !Oct 8, 1:20 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

83. ?Oct 8, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

84. !Oct 8, 12:20 PMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

85. ?Oct 8, 12:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

86. !Oct 8, 12:20 PMsignalseverity 0.11

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

87. ?Oct 8, 11:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

88. !Oct 8, 11:21 AMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

89. ?Oct 8, 11:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

90. !Oct 8, 11:21 AMsignalseverity 0.11

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

91. ?Oct 8, 10:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

92. !Oct 8, 10:20 AMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

93. ?Oct 8, 10:20 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

94. !Oct 8, 10:20 AMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

95. ?Oct 8, 7:00 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

96. !Oct 8, 7:00 AMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

97. ?Oct 8, 7:00 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

98. !Oct 8, 7:00 AMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

99. ?Oct 7, 6:02 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    The 15.5% drawdown from the 30-day high is notable, but no company-specific negative catalysts are evident — recent 8-K filings carry no reported metrics suggesting a guidance cut, earnings miss, or accounting issue, and there are no news headlines in the window to explain the move. However, the macro context is a meaningful headwind: the 5-year forward inflation expectation (T5YIFR) is running 1.9σ above its 24-month trend, signaling elevated rate-sensitivity risk that would pressure a healthcare/medtech name like Baxter, which carries significant debt from its prior restructuring. The combination of an elevated rate environment and sparse filing data (no quantitative metrics available) leaves too much uncertainty to assign a high rebound probability, despite the absence of confirmed deterioration.

100. !Oct 7, 6:02 PMsignalseverity 0.10

     Agent 4 — Dip Buyer (Frozen) — dip_skipped

     The 15.5% drawdown from the 30-day high is notable, but no company-specific negative catalysts are evident — recent 8-K filings carry no reported metrics suggesting a guidance cut, earnings miss, or accounting issue, and there are no news headlines in the window to explain the move. However, the macro context is a meaningful headwind: the 5-year forward inflation expectation (T5YIFR) is running 1.9σ above its 24-month trend, signaling elevated rate-sensitivity risk that would pressure a healthcare/medtech name like Baxter, which carries significant debt from its prior restructuring. The combination of an elevated rate environment and sparse filing data (no quantitative metrics available) leaves too much uncertainty to assign a high rebound probability, despite the absence of confirmed deterioration.

101. ?Oct 7, 4:21 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     BAX is down 10.4% from its 30-day high with no identifiable fundamental catalyst (no negative 8-K disclosures, no guidance cuts, no going-concern language). Options flow shows a bullish tilt (P/C ratio 0.62, call volume at z=1.61 vs put volume at z=0.39), a mild positive signal. However, earnings are 21 days away — within the 15-30 day window — which applies a meaningful headwind (-1 signal) and introduces binary event risk. The Health Care sector is underperforming SPY significantly (−6.40pts on 30d), suggesting the dip is sector-wide rather than idiosyncratic (+1), but the sector weakness itself is a drag. Net signal score: call flow +1, sector underperformance +1, earnings in 15-30 days -1, high 10Y yield (5.31%) as a soft headwind for a rate-sensitive healthcare name -1 = net 0, a marginal/skip outcome. The single strongest positive is the unusual call volume, but it is not accompanied by a cluster insider buy, pushing the marginal case toward a skip. Rebound probability is set just below the buy threshold reflecting the earnings overhang and macro headwinds.

102. ?Oct 7, 4:21 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     BAX is down 10.4% from its 30-day high with no identifiable company-specific negative catalyst — no news headlines, no damaging SEC filings, and no insider selling. The options flow is modestly constructive (P/C ratio 0.62, call volume at z=1.61), suggesting some informed buying interest. However, the setup faces meaningful headwinds: earnings are 21 days away (elevated caution zone), the healthcare sector is underperforming SPY by -6.40pts over 30 days and -4.08pts over 5 days, and the 10Y yield at 5.31% is a structural drag on rate-sensitive healthcare names. The macro environment with elevated forward inflation expectations (T5YIFR 1.8σ above trend) adds further pressure.

103. ?Oct 6, 10:20 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     BAX is down 14.5% from its 30-day high with no news headlines, no insider activity, and no clear fundamental catalyst explaining the drop — suggesting a possible macro or sector-driven selloff rather than company-specific impairment. However, the health care sector (XLV) is actually outperforming SPY over both 5d and 30d (+1.54pts), meaning BAX is dipping while its sector holds up, which points to idiosyncratic weakness with no obvious recovery catalyst. Options flow is neutral (P/C ratio near 1.0, both volumes below average z-scores), providing no confirmation of informed buying. Earnings are 33 days away at consensus $0.53 EPS, which is a manageable but present risk factor worth discounting moderately.

104. ?Oct 6, 10:20 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

105. ?Oct 5, 6:21 PMdecisionconsidered

     Agent 20 — SIR Price/Volume — buy

     [not executed — reserve_floor_or_cash] [cluster_break_up] From 2026-09-24 through 2026-10-02, BAX's PV path formed a tight lateral cluster in the $23.37–$23.68 range on subdued, declining volume (6.6M→6.2M→6.7M→7.4M→4.8M), indicating supply exhaustion and price compression. Today's bar (2026-10-05) breaks decisively above that cluster — closing at $24.22 (+3.11%) on 10.2M shares, a volume z-score of +1.64 vs. the trailing 20-day ADV of 7.2M — which is the hallmark cluster_break_up signal in the SIR 2-D framework: price escaping a low-volume consolidation band on materially expanding demand. Corroborating the read, the prior strong up-volume sessions on 2026-09-21 (11.7M) and 2026-09-22 (7.4M, +3.27%) that arrested the decline, followed by the quiet re-compression, suggest institutional accumulation before today's breakout rather than a random spike. Risks: A failure to hold above the $23.68–$24.00 breakout zone on the next 1–2 sessions (particularly on rising volume) would negate the cluster_break_up read and re-classify the path as distribution or a bull trap. Additionally, the macro backdrop — 5-Year inflation breakevens (T5YIFR at 2.35, +1.8σ above trend) flagging rate sensitivity — poses a systemic headwind for rate-sensitive Health Care names like BAX; a bond-market selloff could override the technical setup entirely.

106. ?Oct 5, 2:20 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     BAX is down 14.5% from its 30-day high with no news headlines, no insider activity, and no clear fundamental catalyst explaining the drop — suggesting a possible macro or sector-driven selloff rather than company-specific impairment. However, the health care sector (XLV) is actually outperforming SPY over both 5d and 30d (+1.54pts), meaning BAX is dipping while its sector holds up, which points to idiosyncratic weakness with no obvious recovery catalyst. Options flow is neutral (P/C ratio near 1.0, both volumes below average z-scores), providing no confirmation of informed buying. Earnings are 33 days away at consensus $0.53 EPS, which is a manageable but present risk factor worth discounting moderately.

107. ?Oct 5, 2:20 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

108. ?Oct 5, 1:21 PMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

109. ?Oct 5, 1:21 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     BAX is down 14.5% from its 30-day high with no news headlines, no insider activity, and no clear fundamental catalyst explaining the drop — suggesting a possible macro or sector-driven selloff rather than company-specific impairment. However, the health care sector (XLV) is actually outperforming SPY over both 5d and 30d (+1.54pts), meaning BAX is dipping while its sector holds up, which points to idiosyncratic weakness with no obvious recovery catalyst. Options flow is neutral (P/C ratio near 1.0, both volumes below average z-scores), providing no confirmation of informed buying. Earnings are 33 days away at consensus $0.53 EPS, which is a manageable but present risk factor worth discounting moderately.

110. ?Oct 5, 11:21 AMdecisionconsidered

     Agent 5 — Dip Buyer (Evolving) — decide: skip

     BAX is down 18.6% from its 30-day high, which qualifies as a meaningful mean-reversion candidate (+1), and the Health Care sector is underperforming the broader market on both 5-day and 30-day bases (+1), suggesting the drop is sector-wide rather than purely idiosyncratic. However, earnings are 49 days away (in the 15-30+ day window, creating an uncertainty premium, -1), options flow is below average on both calls and puts (z=-1.66 for calls, no unusual call signal), there are no insider purchases to support conviction, and the 10Y yield at 4.78% is a structural headwind (-1). The 8-K filings in August lack disclosed metrics, so no fundamental impairment is confirmed, but the evidence stack is thin. Net signal score is approximately 0 to +1 with no strong confirming signals (no cluster buy, no unusual calls), making this a marginal case that falls just short of a buy threshold.

111. ❖Sep 16, 3:59 PMnewsvia finnhub

     Microsoft Leads S&P 500 Stocks Going Nowhere

     A year of stagnation is setting up an important test

112. ▣Sep 10, 8:00 PMjournalstop

     Agent 20 — SIR Price/Volume closed long 66 @ $23.73 (-$200.64)

     intraday stop sweep

113. ❖Sep 9, 11:37 AMnewsvia finnhub

     Baxter International Inc. (BAX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

     Baxter International Inc. (BAX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 12:45 PM EDTCompany ParticipantsAndrew Hider - CEO,...

114. ▣Sep 8, 8:00 PMjournalstop

     Agent 5 — Dip Buyer (Evolving) closed long 1 @ $24.41 (-$2.20)

     Stop hit: close $24.41 ≤ stop $24.48

115. ▣Sep 8, 8:00 PMjournalstop

     Agent 5 — Dip Buyer (Evolving) closed long 1 @ $24.41 (-$2.20)

     intraday stop sweep

116. ▣Sep 8, 8:00 PMjournalstop

     Agent 4 — Dip Buyer (Frozen) closed long 104 @ $24.49 (-$237.64)

     intraday stop sweep

117. ❖Sep 8, 8:05 AMnewsvia finnhub

     Reported Earlier, Medline Prices Secondary Offering Of 75M Class A Shares At $41.00/Share By Blackstone, Carlyle, Hellman & Friedman And ADIA Affiliates

118. ❖Sep 7, 3:38 PMnewsvia finnhub

     BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure

     Baxter raises its 2026 sales and earnings outlook after strong Q2 growth, though manufacturing costs, tariffs and pricing pressure margins.

119. ❖Sep 7, 6:57 AMnewsvia finnhub

     Drug Reconstitution Systems Market Trends, Shares and Growth Opportunities Worldwide 2026-2035 Featuring Profiles of Baxter, ICU Medical, B. Braun, Vetter Pharma, Nipro, SCHOTT-KAISHA

     Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Drug Reconstitution Systems Market - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global drug reconstitution systems market is projected to increase from approximately USD 5.9 billion in 2026 to USD 10.8 billion by 2035, representing a compound annual growth rate (CAGR) of about 7.0% during the forecast period. Market expansion is being supported by the growing pipeline of biologics, biosimilars, vaccines,

120. ❖Sep 2, 9:00 PMnewsvia finnhub

     3 Value Stocks We Keep Off Our Radar

     Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

121. ❖Sep 1, 10:22 AMnewsvia finnhub

     3 Healthcare Stocks We Keep Off Our Radar

     Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 22.1% over the past six months while the S&P 500 was up 12.1%.

122. ❖Aug 30, 10:30 AMnewsvia finnhub

     Everything I Learned from My Hot Chart Summer, and How My 21 Stocks Picks Have Performed.

     Great stock picks are just the start to building a portfolio that can shelter you through whatever the market brings.

123. ▢Aug 25, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 1 @ $26.61

124. ▢Aug 25, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 1 @ $26.61

125. ❖Aug 24, 7:11 PMnewsvia finnhub

     The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

     Embecta (EMBC) looks like a deep value buy: P/E under 3x, 50%+ FCF yield, insider buying and rebound setup.

126. ❖Aug 7, 11:14 AMnewsvia finnhub

     Does Cardinal Health’s New CAO and Recalls Reveal Shifts in Its Risk Profile and Earnings Quality (CAH)?

     In early August 2026, Cardinal Health announced that Anita Zielinski will become Chief Accounting Officer in November, following her interim CFO and senior accounting roles at Baxter and long tenure at Sysco and Ernst & Young, while the company also faced ongoing Class II recalls of subpotent levothyroxine tablets distributed nationwide in the US. This combination of leadership change in Cardinal Health’s finance function and routine but nationwide product recalls comes as analysts are...

127. ❖Aug 4, 1:41 PMnewsvia finnhub

     Baxter International Says Anita Zielinski To Resign As Interim CFO, Effective September 15, 2026

     -SEC Filing

128. ❖Aug 4, 9:25 AMnewsvia finnhub

     Baxter International (BAX) Price Target Increased by 25.96% to 27.05

129. ❖Aug 4, 8:30 AMnewsvia finnhub

     Baxter Announces Cash Tender Offers

     DEERFIELD, Ill., August 04, 2026--Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced that it has commenced cash tender offers (each, an "Offer" and collectively, the "Offers") for the maximum principal amount of validly tendered (and not validly withdrawn) notes set forth below (collectively, the "Notes"), such that the aggregate purchase price, not including accrued and unpaid interest, payable in respect of such Notes will not exceed $500 million.

130. ❖Aug 3, 3:05 PMnewsvia finnhub

     Exploring the top movers within the S&P500 index during today's session.

     Stay updated with the movements of the S&P500 index one hour before the close of the markets on Monday. Discover which stocks are leading as top gainers and losers in today's session.

131. ❖Aug 3, 12:35 PMnewsvia finnhub

     Explore the top gainers and losers within the S&P500 index in today's session.

     Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.

132. ❖Aug 2, 11:06 PMnewsvia finnhub

     Baxter International: The Gains Can Continue, But Should Slow

     Baxter International has shown early signs of a turnaround, with improving execution and raised revenue guidance supporting cautious optimism. Learn more about BAX stock here.

133. ❖Aug 1, 9:10 PMnewsvia finnhub

     Baxter (BAX) Stock Gets Fair Value Boost After Q2 Beat And Higher Targets

     Baxter International is back in focus after the fair value estimate in one widely used model moved from US$21.54 to US$27.29, a change of about 27% that feeds directly into updated price target discussions. Analysts are linking this shift to fresh views on earnings execution, segment performance and medium term growth visibility after the latest Q2 results and guidance. As you read on, you will see how to track these changing views and what to watch as the Baxter International story develops...

134. ❖Aug 1, 5:09 PMnewsvia finnhub

     Baxter International (BAX) Is Up 16.8% After Raising 2026 Sales Outlook And Earnings Guidance

     Baxter International Inc. recently reported past Q2 2026 results, with sales rising to US$2,960 million and quarterly net income increasing to US$126 million compared with the prior year. Alongside this, Baxter raised its 2026 sales growth and adjusted earnings guidance while maintaining a quarterly dividend, signaling management’s confidence in its operating direction. Next, we’ll examine how Baxter’s upgraded 2026 guidance, particularly its higher sales outlook, shapes the company’s...

135. ❖Aug 1, 12:02 AMnewsvia finnhub

     Baxter International Q2 Earnings Call Highlights

     Baxter International (NYSE:BAX) reported second-quarter 2026 results that exceeded its expectations, supported by broad-based sales growth, strong demand in Advanced Surgery and drug compounding, and a $75 million tariff refund. The company raised its full-year organic sales-growth outlook and incre

136. ❖Jul 31, 8:23 PMnewsvia finnhub

     Why Baxter International Stock Skyrocketed by 19% This Week

     The company's second-quarter performance was impressive.

137. ❖Jul 31, 5:10 PMnewsvia finnhub

     S&P 500 ends with its first July decline since 2014. Here are the stocks that led the selloff.

     After a whipsaw end to the month, the stock market’s decline was highlighted by the worst month for chip stocks in 24 years.

138. ❖Jul 31, 4:36 PMnewsvia finnhub

     Citigroup Upgrades Baxter International (BAX)

139. ▣Jul 30, 8:00 PMjournalexpired_settlement

     options_momentum closed long 300 @ $5.16 (+$1,176.21)

     SETTLED 2026-09-17 (mig 257): contract expired 2026-07-31 while the agent was disabled; settled at intrinsic 5.1600 from underlying close 26.16 (Massive, unadjusted). Was carried at stale 7/2 mark 2.0497.

140. ▢Jul 29, 8:00 PMjournal

     Agent 4 — Dip Buyer (Frozen) opened long 104 @ $26.77

141. ▢Jul 29, 8:00 PMjournal

     Agent 20 — SIR Price/Volume opened long 66 @ $26.77

142. ▣Jul 28, 8:00 PMjournaltarget

     Agent 20 — SIR Price/Volume closed long 86 @ $24.76 (+$382.70)

     Target hit: close $24.76 ≥ target $24.37

143. ▢Jul 27, 8:00 PMjournal

     Agent 7 — Day Trader opened long 119 @ $24.42

144. ▣Jul 27, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 119 @ $24.33 (-$11.31)

     EOD forced close — day trader never carries overnight

145. ▢Jul 1, 8:00 PMjournal

     Agent 7 — Day Trader opened long 132 @ $22.49

146. ▣Jul 1, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 132 @ $22.48 (-$1.98)

     EOD forced close — day trader never carries overnight

147. ▣Jun 29, 8:00 PMjournalstop

     options_momentum closed long 400 @ $0.79 (-$77.91)

     Stop: premium $0.79 ≤ trailing floor $0.87 (peak $1.16 × 0.75)

148. ▢Jun 29, 8:00 PMjournal

     options_momentum opened long 300 @ $1.24

149. ▢Jun 24, 8:00 PMjournal

     options_momentum opened long 400 @ $0.98

150. ▣Jun 16, 8:00 PMjournalstop

     options_momentum closed long 500 @ $1.01 (+$64.66)

     Stop: premium $1.01 ≤ trailing floor $1.01 (peak $1.35 × 0.75)

151. ▢Jun 10, 8:00 PMjournal

     Agent 20 — SIR Price/Volume opened long 86 @ $20.31

152. ▢Jun 8, 8:00 PMjournal

     options_momentum opened long 500 @ $0.88

153. ▣May 28, 8:00 PMjournalstop

     options_momentum closed long 900 @ $0.76 (-$141.36)

     Stop: premium $0.76 ≤ trailing floor $0.85 (peak $1.14 × 0.75)

154. ▢May 19, 8:00 PMjournal

     options_momentum opened long 900 @ $0.92